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1. Introduction 
Hamster white fat cells are known to display, like 
the human adipocytes [ 11, a mixed (Y- and fl-adren- 
ergic sensitivity [2,3], which set these cells apart from 
the more frequently used and almost exclusively 
P-sensitive rat white adipocytes [4]. Methods mea- 
suring the binding of the labeled antagonist [3H]- 
dihydroergocryptine have been successfully used for 
the direct identification of cr-adrenergic receptors in 
different tissues [5--g]. Applying these binding 
techniques to a ‘crude’ membrane fraction prepared 
from hamster adipocytes, we have identified and 
characterized specific binding sites for [3H]DHEC in 
this preparation [9]. Although most of the character- 
istics expected of true physiological a-adrenergic 
receptors were fulfilled by these binding sites [9], 
some of their properties suggested that these sites 
may be heterogeneous or that only a part of them 
may represent the true a-receptor sites. 
This has led us to reexamine in detail some of the 
properties of these [3H]DHEC binding sites. We 
report here the subcellular localization of these sites, 
the results of competition experiments using two 
highly selective at- and olz-adrenergic antagonists, 
prazosin and yohimbine [lo- 111 and finally binding 
data obtained with membranes treated under condi- 
tions shown to induce an irreversible block of the fat 
cell physiological a-responsiveness. We show that 
[3H]DHEC binding sites are almost exclusively 
Abbreviations: DHEC, dihydroergocryptine; cyclic AMP, 
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localized in the adipocyte plasma membrane and are 
made up of two components which can be classified 
at least in part as al- and cu,-receptor subtypes. 
2. Experimental 
2.1. Chemicals 
[jH]DHEC (spec. act. 22 Ci/mmol) was obtained 
from the Radiochemical Centre (Amersham). Fresh 
stock solutions were prepared and diluted for the 
binding assays as in [9]. Prazosin and clonidine were 
gifts from Pfizer (France) and Boehringer (Ingelheim), 
respectively. Yohimbine, (-)epinephrine, (-)-nore- 
pinephrine, and dopamine were from Sigma. Cyclic 
[3H]AMP and cyclic AMP-binding protein were 
purchased from the Radiochemical Centre, Amersham. 
The sources of all the other reagents have been 
described [9]. Fresh stock solutions of phentolamine, 
phenoxybenzamine, prazosin, yohimbine and clon- 
idine were prepared as in [6,9,11]. 
2.2. Preparation of crude membranes and subcellular 
fractions 
Epididymal fat pads from fed golden hamsters 
(Charles River) 95-105 g, were pooled and isolated 
fat cells prepared as in [3]. Isolated fat cells were 
resuspended in medium I (0.25 M sucrose, 1 mM 
EDTA, 10 mM Tris-HCl, pH 7.4) and disrupted 
according to 1121. After breakage, the suspension 
was centrifuged, washed 3 times and resuspended as 
in [ 131. The final pellet (crude membrane) was 
resuspended in medium II (10 mM MgClz, 50 mM 
Tris-HCl) resulting in a suspension containing 
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2-2.5 mg protein/ml which was used in binding 
assays. Adipocyte plasma membranes, mitochondrial 
and microsomal membrane preparations were pre- 
pared as in [ 141. These fractions were resuspended in 
medium II, stored for 24 h in liquid nitrogen and 
assayed for [3H]DHEC binding. 
2.3. Binding assay 
Binding assays were done by a slight modification 
of the method in [6 1. Protein (200 pg) was usually 
incubated with [3H]DHEC in 150 fl total vol. of 
medium II for 10 mm with shaking at 37’C. Incuba- 
tions were terminated by adding 5 ml incubation 
buffer, followed by a rapid vacuum filtration of the 
suspension through a Whatman GFC glass fiber filter. 
Filters were rapidly washed with 15 ml buffer. The 
filtration and wash steps were completed in <30 s. 
Filters were dried, added to 10 ml scintillation cock- 
tail (MI 96, Packard) and counted with an efficiency 
of 40%. Non-specific binding was determined by 
measuring the radioactivity retained on filters when 
incubations were performed with a large excess (10 
m) of phentolamine. All values refer to specific 
binding which averaged 75--85% of the total counts 
bound and which was defined as total radioactivity 
bound minus non-specific binding. As attested by 
chromatographical studies [6], no degradation of 
the radiolabeled ligand could be detected during the 
binding incubations. 
binding found in the plasma membrane fraction (not 
shown). As documented by 5’nucleotidase analysis 
and as pointed out [ 171, the small amount of [3H]- 
DHEC binding to the microsomal fraction was prob- 
ably accounted for by some contamination of this 
fraction with plasma membranes. Thus, and because 
the preparation of the plasma membrane fraction is 
a multistep process requiring several hours, all the 
following experiments were performed on micro- 
some-free crude membranes. 
Studies concerned with a-adrenergic receptors in 
brain [11,12], heart [18] and smooth muscle [19,20] 
have clearly shown that [3L]DHEC could bind in 
these tissues to two different types of sites. To 
determine whether such a situation could also apply 
to hamster fat cells, inhibition of [3H]DHEC binding 
by different a-adrenergic antagonists and agonists 
were studied and the resulting data transformed as 
log-logit plots. As shown in table 1, the a-antagonists 
phentolamine and phenoxybenzamine potently 
competed for the [3H]DHEC binding sites with 
respective ECSO values of 120 and 180 nM; the same 
applied for the o-agonists (-)epinephrine (ECSO 
= 400 nM) and (-)-norepinephrine (fX?~e = 600 
nM). In contrast, dopamine and serotonine were 
weak competitors (_!X~e = 100 and 300 PM, 
respectively). Log-logit plots derived from these 
displacement curves consistently displayed slopes less 
2.4. Other determinations 
Incubation of fat cells and determination of cyclic 
AMP were done as in [3,15]. Protein was determined 
according to [ 161. 
Table 1 
Inhibition by various drugs of the specific [‘HI dihydroergo- 
cryptine binding to hamster adipocyte membranes 
Drugs EC,, Log-logit 
(nM) slopes 
3. Results and discussion 
The subcellular distribution of [3H]DHEC binding 
sites in hamster adipocytes was studied by measuring 
the amount of [3H]DHEC which specifically binds to 
fractions enriched in plasma membranes, mitochon- 
dria and microsomes, when these fractions are 
incubated for 10 min at 37°C in the presence of 5 nM 
[jH]DHEC. Of the fractions tested, binding was 
predominantly localized in the plasma membrane 
fraction. Indeed, taking into account the recovery 
of each fraction, specific binding of [3H]DHEC 
was undetectable in the mitochondrial fraction 
whereas in microsomes it was <15% of the specific 
(-)-Epinephrine 400 0.48 
(-)-Norepinephrine 600 0.55 
Phentolamine 120 0.60 
Phenoxybenzamine 180 0.48 
Dopamine 100 000 0.71 
Serotonine 300 000 0.75 
Hamster adipocyte membranes were incubated with [3H]- 
DHEC (8.5 nM) alone or in combination with increasing 
concentrations of the indicated drugs. After 10 min incuba- 
tion, the amount of [aH]DHEC remaining specifically bound 
was determined. Log-logit plots were drawn and slope 
values calculated by regression analysis. EC,, values refer 
to the concentration of each drug causing 50% inhibition of 
[3H]DHEC binding. Values are mean of 2 expt with binding 
at each drug concentration assayed in duplicate in each 
experiment 
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than unity to suggest displacement by these com- 
pounds at two different [3H]DHEC binding sites 
(table 1). 
This was confirmed by the following experiments 
in which the steady-state binding of [3H]DHEC to 
hamster adipocyte membranes was studied as a func- 
tion of [3H]DHEC concentration. As shown in fig.1, 
the [3H]DHEC saturation binding curve was appar- 
ently biphasic with a break at -3 nM. A Scatchard 
analysis [21] of these data (fig.1, inset) suggested two 
straight lines consistent with the existence of two 
orders of [3H]DHEC binding sites. One set of binding 
sites had high affinity (Kd 2 nM) but low binding 
capacity (30% of the total [3H]DHEC binding sites), 
whereas the other set of sites displayed low affinity 
but high binding capacity and possibly apparent posi- 
tive cooperativity (Kd 11 nM,B,, = 0.68 pmol/mg 
protein, Hill number = 1.4, values calculated after 
subtraction of the contribution of the high affinity 
sites). These results are thus different from the data 
in [9] where a single homogeneous class of binding 
sites was reported. This discrepancy appears related 
to the fact that in the former study, the binding of 
[3H]DHEC at low ligand concentrations was deter- 
mined from a more limited number of [3H]DHEC 
concentrations than here, thus rendering the data 
inaccurate. 
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Fig.1. Specific binding of [“HIDHEC to hamster adipocyte 
membranes as a function of [“HI DHEC concentration. Ham- 
ster adipocyte membranes were incubated with the indicated 
concentrations of [‘HI DHEC and specific binding was deter- 
mined as in section 2. Each value is the mean of 3 determina- 
tions from representative xperiment, each experiment being 
repeated 3 times. Inset: Scatchard plot of [‘H]DHEC binding. 
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Fig.2. Displacement of [ aH] DHEC bound to hamster adi- 
pocyte membranes by or-adrenergic agonist and antagonists. 
Membranes (200 clg protein) were incubated at 37°C with 
2.5 nM (A) or 8.5 nM (B) [sH]DHEC in the absence (con- 
trol) 01 presence of various concentrations of clonidine (o), 
yohimbine (0) or prazosin (A). After 10 min incubation, the 
amount of [ ‘H]DHEC remaining bound was determined as 
in section 2. Each point is the mean of 3 determinations from 
one representative xperiment, each experiment being 
repeated at least twice. 
For further analysis, we studied at two different 
[3 ] DHEC concentrations, the displacement of this 
ligand by two selective al- and a*-antagonists, respec- 
tively, prazosin and yohimbine [ 11,12,18,19] and by 
one cuz-agonist, clonidine [22]. At 2.5 nM [3H]DHEC, 
a concentration labeling predominantly the apparent 
high affinity [3H] DHEC binding sites (fig.l), yohim- 
bine and clonidine showed similar biphasic competi- 
tion curves (fig2A) suggesting the existence of two 
classes of binding sites for each of these drugs: in 
fact, both of these drugs initially displaced with high 
affinity 60-70% of the labeled sites and displaced 
only with low affinity the remaining binding sites. In 
contrast, prazosin was a weak competitor under these 
conditions. From fig.2A, it appears likely that the 
70% of the labeled sites which have quite high affin- 
ity for clonidine and yohimbine are presumably (1~~ 
by nature, although the lower affinity sites for 
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yohimbine and clonidine are hard to classify since 
their affinity is also higher than that of prazosin. At 
8.5 nM [‘H]DHEC, at which 60-70% of th.e labeled 
sites represent he low affinity [3H]DHEC binding 
sites, the competition curves for yohimbine and 
clonidine were apparently monophasic (fig.2B); under 
the same conditions, prazosin showed a sharp 
biphasic competition curve indicating the existence of 
two apparent orders of sites, one with high affinity 
representing 25% of the labeled sites (maximal com- 
petition between 3 and 300 nM) and one with low 
affinity representing the 75% remaining sites. Thus, 
the bulk of sites (70-75%) which have much higher 
affinity for yohimbine and clonidine than for prazosin 
are clearly CQ. So the proportion of (Y~ receptor 
subtype is about the same whether the [3H] DHEC 
binding sites to be displaced are predominantly the 
high or the low affinity [3H] DHEC binding sites. 
This is not surprising considering reports showing 
that [3H]DHEC labels al-and acz-receptors with equal 
affinity in tissues other than adipose tissue (reviewed 
i231). 
To have a better estimation of the respective pro- 
portions of (vl and (Y~ receptors, experiments were 
performed in which we compared the Scatchard 
plots of [3H] DHEC binding in the absence and in the 
presence of 100 nM prazosin, a concentration which 
saturates the high affinity binding component of this 
antagonist in the competitive experiments depicted 
in fig.2B. As shown in fig.3, maximal binding was 
reduced by 17% in the presence of prazosin. Thus, 
these results provide pharmacological evidence that 
the [3H]DHEC binding sites of hamster fat cell 
membranes are a mixed population of CY~- (17%) and 
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Fig.3. Scatchard plot of the concentration-dependent binding 
of [3H]DHEC in the presence of prazosin. Hamster adipocyte 
membranes were incubated with [ 3H] DHEC as in fig. 1, in 
the absence (0) or presence of 100 nM prazosin (a). Each 
point is the mean of 3 determinations from 1 expt. 
(Ye- (83%) receptors subtypes, a possibility which has 
been evoked in earlier physiological studies on the 
role of a-adrenergic receptors in the control of 
glucose metabolism in these cells [24]. 
In order to test the physiological significance of 
both these high and low affinity [3H]DHEC binding 
sites, the binding of [3H] DHEC was studied in mem- 
branes preexposed to conditions inducing an irrevers- 
ible block of the cy-adrenergic responsiveness of the 
intact cells. These conditions consisted in incubating 
Table 2 
Influence of a preliminary incubation with phenoxybenzamine on the ol-adrenergic responsiveness of
hamster fat cells 
Preincuba- 
tion 
Cyclic AMP produced @mol. g lipid-’ .30 min-’ ) in response to 
Epinephrine Epinephrine (50 PM) + 
(50 PM) Phenoxybenzamine (100 CLM) 
Control 
Phenoxybenzamine 
(100 clM) 
9.99 f 0.52 
22.64 t 3.92 
(P < 0.001) 
18.70 t 1.43 
21.50 + 1.97 
(P > 0.1) 
Fat cells were preincubated at 37°C in the absence (control) or presence of phenoxybenzamine 
(100 MM). After 30 min, cells were repeatedly washed and reincubated with epinephrine alone or in 
combination with phenoxybenzamine. After 30 min, total cyclic AMP (cells + medium) was deter- 
mined. Each value is the mean f SE of 4 incubations 
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fat cells for 30 min at 37’C with 100 pM (the concen- 
tration eliciting the maximal rise in the epinephrine- 
induced cyclic AMP production [unpublished]) of 
phenoxybenzamine, an a-antagonist known to block 
irreversibly the a-adrenergic receptors in different 
tissues [20,25,26]. After repeated washing, such pre- 
treated fat cells had lost their a-adrenergic respon- 
siveness since the cyclic AMP produced by these 
cells after a subsequent incubation with epinephrine 
(50 PM) alone or in combination with phenoxyben- 
zamine (100 PM) were not only equivalent but also 
identical with the cyclic AMP produced by epineph- 
rine plus phenoxybenzamine in control cells 
(preincubated in the absence of phenoxybenzamine) 
(table 2). These experimental conditions were thus 
applied to adipocyte membranes which were first 
incubated with 100 /.IM phenoxybenzamine, repeat- 
edly washed and subsequently assayed for [3H]DHEC 
binding. Under these conditions, specific binding of 
[3H]DHEC to both the high and low affinity sites was 
completely suppressed in these membranes (not 
shown), indicating that these [3H]DHEC binding sites 
do, in fact, represent at least in part the functional 
ol-receptors of the hamster fat cells. 
The high potency of clonidine and yohimbine to 
displace most of the specific [3H]DHEC binding sites 
would be an argument in favour of the presynaptic 
character of these Luz-binding sites [27]. This seems, 
however, highly unlikely because of the nature of 
the membranous preparation used which was not 
directly obtained from adipose tissue homogenates 
but from neural tissue-free fat cells. Therefore ham- 
ster fat cells can be considered as an additional 
example of a non-neural tissue [ 19,231 in which a 
post-synaptic cw,-receptor subtype can be identified 
by radio-ligand binding studies. 
A relationship between binding data and physiolog- 
ical cw-adrenergic responses provides strong evidence 
in favour of the existence of functional al- and (Ye- 
adrenergic receptor subtypes in hamster fat cell mem- 
branes. Experiments using [3H]norepinephrine, 
[3H]prazosin and [3H]clonidine are currently under- 
way to determine the affinities of these receptors, 
their metabolic role and their possible hormonal 
regulation which is suggested by our observation that 
both the a-adrenergic responsiveness and the number 
of specific [“HIDHEC binding sites of hamster fat 
cells are variable with age and cell size (unpublished) 
and are decreased by thyroid hormones [28]. Such 
experiments would also be helpful in the understanding 
of the molecular mechanisms which underlie cu-recep- 
tor mediated adrenergic stimulation, namely the 
effects linked to the binding of catecholamine to 
cu-receptors and the role played by calcium [29,30]. 
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